Beqvez, a one-time gene therapy, offers hope to patients with moderate to severe hemophilia B who use regular factor IX prophylaxis, suffer severe hemorrhages, or recurrent serious bleeding.
![FDA Approves Pfizer’s Beqvez for the Treatment of Adults with Moderate to Severe Hemophilia B](https://onclive.s3.amazonaws.com/onclive_630x1200.png)
Beqvez, a one-time gene therapy, offers hope to patients with moderate to severe hemophilia B who use regular factor IX prophylaxis, suffer severe hemorrhages, or recurrent serious bleeding.